Key result
Late-onset ARVC is linked to ~64% lower incidence of electrical storm versus early-onset disease.
Why the study?
Does late-onset ARVC (>40 years) have a different clinical presentation and long-term outcome compared to early-onset ARVC (≤40 years)?
Cohort (n=76)
Does late-onset ARVC (>40 years) have a different clinical presentation and long-term outcome compared to early-onset ARVC (≤40 years)?
Late-onset ARVC (>40 years) is associated with a less severe clinical course, slower ventricular tachycardias, fewer ICD therapies, and a lower risk of progression to heart failure compared to early-onset disease.
Diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) is often made after arrhythmias are detected in the second or third decade but can also present later. The authors sought to compare the phenotypes and the long-term outcome between patients with early- vs late-onset ARVC. Patients with a definite ARVC diagnosis fulfilling the 2010 Task Force criteria and symptomatic arrhythmias at initial presentation were candidates. Based on age of onset of symptoms, patients were divided into 2 groups: early ARVC: ≤40 years (E-ARVC) and late ARVC: >40 years (L-ARVC). Clinical characteristics and outcomes were compared between the groups. Between 2004 and 2024, 76 probands were included. Fifty patients were in the E-ARVC group (median 27.5 years) and 26 in L-ARVC (45.5 years). Gender, genotype, family history, and RV function did not show any statistical differences. Patients with L-ARVC were significantly less likely to present with cardiac arrest or syncope than E-ARVC patients (7.6% vs 40.0%; P = 0.003). During follow-up, patients with L-ARVC had a slower VT cycle length (321.5 ms vs 259.5 ms; P < 0.001), lower incidence of electrical storm (19.2% vs 54.0%; P = 0.004), and fewer ICD therapies (42.3% vs 80.0%; P < 0.001) than patients with E-ARVC. During a mean follow-up of 11.1 years, there was a lower incidence of heart failure in L-ARVC patients (46.0% vs 19.2%; P = 0.028). VT ablation was performed with similar success rates. Clinical onset of ARVC after age 40 years is usually less severe than early-onset disease, despite similar structural phenotype, and is associated with slower VTs and less VT storm, and appears to have a lower risk of progression to clinical heart failure.
No takes yet. Share an insight, caveat, or question.
Uetake et al. (2025) conducted a cohort in Arrhythmogenic right ventricular cardiomyopathy (ARVC) (n=76). Late-onset ARVC (>40 years) vs. Early-onset ARVC (≤40 years) was evaluated on Incidence of electrical storm (p=0.004). Late-onset ARVC (>40 years) was associated with a significantly lower incidence of electrical storm compared to early-onset disease (19.2% vs 54.0%; P=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: